

MEDICATION-ASSISTED TREATMENT OPTIONS GUIDE

For Health Care Providers

June 2021

As part of Cigna's ongoing commitment to reducing opioid use among customers, we have created this Medication-Assisted Treatment (MAT) Options Guide, which includes MAT medications and key clinical information to help you determine which options may be most beneficial for your patients.

- For non-injectable MAT prescriptions call Cigna Pharmacy: 800.622.5579
- For injectable MAT prescriptions (i.e. VIVITROL®, SUBLOCADE®) call Accredo: 877.826.7657

Medication route of administration	Type treatment effect	Recommended patient audience	Side effects	Average cost/ 30-day Rx
Injectable naltrexone Viivitrol® Monthly IM injection	Antagonist <i>Blocks the pleasurable effects of opiates to reduce the likelihood of relapse and opiate overdose</i>	For patients who may struggle to remember to take a daily medication Patient is opioid free for seven to 10 days before starting Avoid use in pregnancy – risk of abortion, stillbirth, and other adverse events	Nausea, headache, weakness, and injection site reactions Rare hepatotoxicity, avoid use with acute hepatitis and hepatic failure	\$1,675
Lucemyra® Oral three times a day dosing	Central alpha-2 adrenergic agonist <i>*Not an opioid*</i> <i>Reduces opioid cravings and withdrawal effects</i>	Indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults May be used as an adjunct to buprenorphine or methadone Avoid using Lucemyra® in patients with congenital long QT syndrome	Hypotension, prolonged QT interval, and bradycardia	\$2,084

Together, all the way.™



All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

Medication route of administration	Type treatment effect	Recommended patient audience	Side effects	Average cost / 30-day Tx
Buprenorphine Probuphine, Sublocade®, Subutex SL tabs/generics <i>Probuphine®: implant (q 6mo)</i> <i>Sublocade®: monthly SC injection</i> <i>SL tabs: oral, daily dosing</i>	Mixed agonist- antagonist <i>Prevents opiate withdrawal and cravings; blocks against opiate overdose through its antagonist action</i>	For patients with low likelihood of misuse potential.	Headache, dizziness, trouble sleeping, and tingling sensation	Probuphine: \$ 2,750 Sublocade®: \$1,830 SL tabs: \$82
Buprenorphine plus naloxone Suboxone®/generics, Zubsolv®, Bunavail <i>Orally – taken once daily</i>	Mixed agonist- antagonist <i>Prevents opiate withdrawal and cravings and also blocks against opiate overdose</i> <i>The added naloxone decreases the misuse potential</i>	For patients with opioid use disorder with access to an office-based licensed prescriber Potential for misuse	Constipation, dizziness, drowsiness, and headache	Buprenorphine plus naloxone SL tabs or films: \$80 Bunavail: \$400 Zubsolv®: \$425
Methadone Dolophine®, Methadose™ <i>Oral, taken daily. Administered by a Substance Abuse and Mental Health Services Administration (SAMSHA)- certified treatment program.</i>	Agonist <i>Prevents opiate withdrawal and cravings, but at prescribed doses, does not create opiate-like effects</i>	For patients with the proximity and availability to attend a clinic daily Potential for misuse	Sleep problems, anxiety, restlessness, dry mouth, nausea, and decreased sex drive	\$13

Together, all the way.™



All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.